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Purpose: To investigate relationships between computer-extracted breast 
magnetic resonance (MR) imaging phenotypes with multigene 
assays of MammaPrint, Oncotype DX, and PAM50 to assess 
the role of radiomics in evaluating the risk of breast cancer 
recurrence.
Materials and 
Methods:
Analysis was conducted on an institutional review board–ap-
proved retrospective data set of 84 deidentified, multi-insti-
tutional breast MR examinations from the National Cancer 
Institute Cancer Imaging Archive, along with clinical, histopath-
ologic, and genomic data from The Cancer Genome Atlas. The 
data set of biopsy-proven invasive breast cancers included 74 
(88%) ductal, eight (10%) lobular, and two (2%) mixed can-
cers. Of these, 73 (87%) were estrogen receptor positive, 67 
(80%) were progesterone receptor positive, and 19 (23%) 
were human epidermal growth factor receptor 2 positive. For 
each case, computerized radiomics of the MR images yielded 
computer-extracted tumor phenotypes of size, shape, margin 
morphology, enhancement texture, and kinetic assessment. 
Regression and receiver operating characteristic analysis were 
conducted to assess the predictive ability of the MR radiomics 
features relative to the multigene assay classifications.
Results: Multiple linear regression analyses demonstrated significant as-
sociations (R2 = 0.25–0.32, r = 0.5–0.56, P , .0001) between 
radiomics signatures and multigene assay recurrence scores. 
Important radiomics features included tumor size and enhance-
ment texture, which indicated tumor heterogeneity. Use of ra-
diomics in the task of distinguishing between good and poor 
prognosis yielded area under the receiver operating character-
istic curve values of 0.88 (standard error, 0.05), 0.76 (standard 
error, 0.06), 0.68 (standard error, 0.08), and 0.55 (standard 
error, 0.09) for MammaPrint, Oncotype DX, PAM50 risk of 
relapse based on subtype, and PAM50 risk of relapse based on 
subtype and proliferation, respectively, with all but the latter 
showing statistical difference from chance.
Conclusion: Quantitative breast MR imaging radiomics shows promise for 
image-based phenotyping in assessing the risk of breast cancer 
recurrence.
q RSNA, 2016
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Breast Invasive Carcinoma and TCIA 
initiatives according to institutional 
review board–approved, Health In-
surance Portability and Accountabil-
ity Act–compliant protocols. Analyses 
were conducted on deidentified data 
only. Thus, patient selection basically 
included all cases available through the 
TCGA TCIA repository. Although this 
data set of MR images is not state of 
the art in terms current clinical pro-
tocols, it is unique in that by being 
part of the TCGA, assessment rela-
tive to gene assays and other genomic 
analyses is possible, which is not read-
ily available in current clinical radiol-
ogy departments.
At the time of our study, only 108 
cases of the entire TCGA breast cancer 
data set had breast MR images, which 
had been collected and made available 
in the TCIA (http://www.cancerimaging 
archive.net) (25). However, to minimize 
variations in image quality across the 
multi-institutional cases, in our analysis, 
we included only breast MR imaging 
studies acquired with 1.5-T GE Medical 
Methods for computer-aided di-
agnosis and quantitative characteriza-
tion—that is, image-based tumor phe-
notyping—of cancers on breast images 
(obtained with mammography, ultra-
sonography, and magnetic resonance 
[MR] imaging) have been in develop-
ment for decades (10–12) and have 
recently received a renewed interest 
with the expansion beyond detection 
and diagnosis. Image-based tumor phe-
notypes by using computer vision tech-
niques are being evaluated in terms of 
their relationship to breast cancer in-
vasiveness, stage, lymph node involve-
ment, molecular subtypes (11–18), and 
genomics (19–23).
Researchers involved with The Can-
cer Genome Atlas (TCGA) have dem-
onstrated the role of gene expression 
profiles in characterizing TCGA breast 
cancer (24). In addition, the National 
Cancer Institute started collecting the 
corresponding MR imaging data for 
some TCGA tumors and having the 
data stored within The Cancer Imaging 
Archive (TCIA) (25). The purpose of 
our study was to investigate the rela-
tionships between breast MR comput-
er-extracted image phenotypes (CEIPs)
with gene expression assays of Mam-
maPrint, Oncotype DX, and PAM50 to 
assess the potential role of MR imag-
ing radiomics in evaluating the risk of 
breast cancer recurrence.
Materials and Methods
Study Population and MR Images
Patient data were obtained from 
the National Cancer Institute TCGA 
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Advances in Knowledge
 n Regression models of MR com-
puter-extracted image phenotypes 
(CEIPs)—that is, breast MR im-
aging radiomics—are significantly 
associated with breast cancer risk 
of recurrence as predicted with 
research-based multigene assays, 
including MammaPrint, Oncotype 
DX, and PAM50 (R2 = 0.25–0.32, 
r = 0.50–0.56, P , .0001); impor-
tant CEIPs included tumor size, 
as well as enhancement texture 
patterns that potentially indicate 
tumor heterogeneity.
 n Use of radiomics in the task of 
distinguishing between good and 
poor prognosis in terms of esti-
mated risk of recurrence yielded 
area under the receiver oper-
ating characteristic curve values 
of 0.88 (standard error, 0.05), 
0.76 (standard error, 0.06), 0.68 
(standard error, 0.08), and 0.55 
(standard error, 0.09) for Mam-
maPrint, Oncotype DX, PAM50 
risk of relapse based on subtype, 
and PAM50 risk of relapse based 
on subtype and proliferation, 
respectively.
Implications for Patient Care
 n Quantitative breast MR imaging 
radiomics shows promise as a 
means for image-based tumor 
phenotyping in assessing the risk 
of breast cancer recurrence.
 n Computerized MR imaging tumor 
phenotyping may yield quantita-
tive predictive models of breast 
cancer for precision medicine 
and may potentially affect patient 
treatment strategy.
Advances in gene expression pro-filing by using microarray-based technologies have allowed investi-
gators to study the complexity of breast 
tumors (1–9). Various investigators 
have used and developed methods for 
gene expression analyses (1,2) to re-
late breast cancer expression profiles 
to prognosis and risk of recurrence. 
These include the 70-gene MammaP-
rint microarray assay (Agendia, Am-
sterdam, the Netherlands) (3,4), the 
21-gene Oncotype DX assay (Genomic 
Health, Redwood City, Calif) (5–7) for 
predicting breast cancer recurrence, 
and the 50-gene PAM50 assay (Prosig-
na; Nanostring Technologies, Seattle, 
Wash) (8,9) for identifying clinically 
relevant molecular subtypes of breast 
cancer. Outputs from such multiple-
gene assays are expected to be useful 
in the management of breast cancer by 
predicting prognosis and/or effective-
ness of treatment.
384 radiology.rsna.org n Radiology: Volume 281: Number 2—November 2016
BREAST IMAGING: MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence Li et al
years; E.J.S., 4 years; J.M.N., 5 years; 
M.G., 29 years; and E.A.M., 25 years; 
the other five radiologists were nonau-
thors). The tumor location was deter-
mined by means of consensus by using 
the radiologist reviewer information. 
This location of the primary tumor in 
each MR examination was made avail-
able in the subsequent computerized 
quantitative image analysis.
Recurrence Scores Obtained with 
Multigene Assays
The genomic-based scores for the mul-
tigene assays that served as the refer-
ence standards were determined at the 
University of North Carolina, which 
yielded “research-based” MammaP-
rint, Oncotype DX, and PAM50 assays 
(Table 1). It is important to note that 
for these TCGA samples, the clinical 
assay results were not available—that 
is, only the “research-based” assay 
outputs were available. Each statisti-
cal model as described in the original 
gene assay articles (3–9) was applied 
to the messenger RNA sequencing 
data to obtain research-based bioinfor-
matics estimates of the risk of recur-
rence scores. The assays were run on 
a set of 1030 tumors and 110 adjacent 
be downloaded and cited in future works 
by using http://dx.doi.org/10.7937/K9/
TCIA.2014.8SIPIY6G. The mean age 6 
standard deviation of the 84 patients was 
53.6 years 6 11.6, and the range was 
29–82 years.
For each examination, T1-weighted 
dynamic contrast material–enhanced MR 
images were analyzed for this study, in-
cluding one unenhanced and three to 
five contrast-enhanced images obtained 
by using a T1-weighted three-dimension-
al spoiled gradient-echo sequence with 
a gadolinium-based contrast agent (Om-
niscan; Nycomed-Amersham, Princeton, 
NJ). In-plane resolution ranged from 
0.53 to 0.86 mm, spacing between sec-
tions ranged from 2 to 3 mm, flip angle 
was 10°, acquisition matrix was 256 3 
192, and temporal resolution was ap-
proximately 110 seconds.
Images from each breast MR exam-
ination were reviewed, and the lesion 
was located independently by three of 11 
breast radiologists who were members 
of the TCGA Breast Phenotype Research 
Group by using ClearCanvas software 
(ClearCanvas, Toronto, Ontario, Cana-
da) (26). The breast imaging experience 
of the 11 radiologists ranged from 4 to 
29 years (E.S.B., 14 years; G.J.W., 25 
Systems imaging units (Milwaukee, Wis). 
Our database excluded 14 studies per-
formed by using Siemens imaging units 
(Malvern, Pa) and one study performed 
by using a 3-T GE Medical Systems im-
aging unit, thus resulting in a total of 93 
cases. We then excluded cases that had 
missing images for the dynamic sequence 
(one patient) or that, at the time, did not 
have gene expression analysis findings 
available (eight patients). After adhering 
to these criteria, the study data set of 
84 patients with invasive breast cancer 
was finalized, with MR imaging exami-
nations conducted at four institutions: 
Memorial Sloan-Kettering Cancer Cen-
ter, Mayo Clinic, University of Pittsburg 
Medical Center, and Roswell Park Can-
cer Institute. The number of cases con-
tributed by each institution, respectively, 
were nine (date range, 1999–2002), 
five (date range, 1999–2003), 46 (date 
range, 1999–2004), and 24 (date range, 
1999–2002). The cancers included 74 
ductal (88%), eight lobular (10%), and 
two mixed (2%) cancers. Of these, 73 
(87%) were estrogen receptor (ER) pos-
itive, 67 (80%) were progesterone re-
ceptor (PR) positive, and 19 (23%) were 
human epidermal growth factor receptor 
2 (HER2) positive. This set of images can 
Table 1
Distribution of Cases in the Database: Tabulation of Receptor Status (ER, PR, and HER2), MammaPrint, Oncotype DX, and PAM50 Gene 
Assays of the Study Data Set
Gene Assay Test and Prognosis Total (%) ER Positive (%) ER Negative (%) PR Positive (%) PR Negative (%) HER2 Positive (%) HER2 Negative (%)
All cases … 87 (73/84) 13 (11/84) 80 (67/84) 20 (17/84) 23 (19/84) 77 (65/84)
MammaPrint
 Good prognosis 83 (70/84) 98 (69/70) 1 (1/70) 90 (63/70) 10 (7/70) 20 (14/70) 80 (56/70)
 Bad prognosis 17 (14/84) 28 (4/14) 71 (10/14) 28 (4/14) 71 (10/14) 36 (5/14) 64 (9/14)
Oncotype DX
 Lowest tertile (lowest risk) 30 (25/84) 100 (25/25) 0 (0/25) 96 (24/25) 4 (1/25) 20 (5/25) 80 (20/25)
 Middle tertile 38 (32/84) 100 (32/32) 0 (0/32) 97 (31/32) 3 (1/32) 9 (3/32) 91 (29/32)
 Top tertile 32 (27/84) 59 (16/27) 41 (11/27) 44 (12/27) 56 (15/27) 41 (11/27) 59 (16/27)
PAM50 ROR-S
 Low recurrence risk 62 (52/84) 100 (52/52) 0 (0/52) 94 (49/52) 6 (3/52) 17 (9/52) 83 (43/52)
 Medium recurrence risk 20 (17/84) 94 (16/17) 6 (1/17) 82 (14/17) 18 (3/17) 18 (3/17) 82 (14/17)
 High recurrence risk 18 (15/84) 33 (5/15) 67 (10/15) 27 (4/15) 73 (11/15) 47 (7/15) 53 (8/15)
PAM50 ROR-P
 Low recurrence risk 40 (34/84) 100 (34/34) 0 (0/34) 97 (33/34) 3 (1/34) 24 (8/34) 76 (26/34)
 Medium recurrence risk 44 (37/84) 89 (33/37) 11 (4/37) 81 (30/37) 19 (7/37) 16 (6/37) 84 (31/37)
 High recurrence risk 15 (13/84) 46 (6/13) 54 (7/13) 31 (4/13) 69 (9/13) 38 (5/13) 62 (8/13)
Note.—Numbers in parentheses are the data used to calculate the percentages.
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By using techniques developed in 
prior studies, a total of 38 CEIPs of 
the breast tumors were extracted auto-
matically in three dimensions from the 
segmented tumors on MR images to de-
scribe (a) size (linear size, volume, and 
surface area), (b) shape (sphericity and 
irregularity), (c) margin morphologic 
appearance (margin sharpness, vari-
ance of margin sharpness, and variance 
of radial gradient histogram, which 
is used to assess tumor spiculation) 
(30), (d) enhancement texture (calcu-
lated on the first postcontrast images 
by using the gray-level co-occurrence 
matrix, yielding features of homoge-
neity, entropy, gray-level dependence, 
and local image variation [33,34]), (e) 
kinetic curve assessment (based on 
the most enhancing voxels within a le-
sion and including maximum contrast 
enhancement, time to peak, uptake 
rate, washout rate, curve shape index, 
enhancement at the first contrast-en-
hanced time point, signal intensity en-
hancement ratio, total rate variation, 
and normalized total rate variation 
[32]), and (f) enhancement-variance ki-
netics (maximum variance of enhance-
ment, time to peak, variance increase 
rate, and variance decrease rate [31]). 
Note that these 38 tumor phenotypes 
research versions of MammaPrint (3) 
and Oncotype DX (5) were applied to 
the messenger RNA sequencing data 
as described previously (28), with the 
scaling exception used for Oncotype 
DX noted earlier.
Computerized Quantitative MR Image 
Analysis of the Tumors
Quantitative MR imaging radiomics 
analysis was conducted to yield the 
CEIPs (Fig 1). Note that we do not 
present here the details of the tech-
nical and/or robustness aspects of 
the computer-extracted MR imag-
ing phenotypes, as they have already 
been validated and reported through 
various peer-reviewed publications 
(29–34).
From the consensus location iden-
tified by the radiologists, computer-
ized three-dimensional tumor seg-
mentation was conducted by yielding 
delineation of each primary breast 
tumor from the surrounding paren-
chyma (29). Note that this automated 
segmentation technique has been 
used over the past 10 years on hun-
dreds of breast lesions imaged with 
different MR imaging units, with re-
sults comparable to radiologists’ de-
lineations (29,34).
normal samples, and the results were 
extracted for the 84 samples used. The 
relationships between the different 
gene assays—that is, the correlations 
between the continuous output values 
from the different “research-based” 
gene assays (the “reference standards” 
in this study)—showed relatively high 
Spearman correlations (approximately 
0.81–0.87). However, the categori-
zation of these values into low-, me-
dium-, or high-risk groups yielded con-
flicting outputs from one of the three 
multigene tests (ie, Oncotype DX), 
most likely due to the application of 
the published assay thresholds based 
on quantitative real-time polymer-
ase chain reaction on the messenger 
RNA sequencing expression data. 
Therefore, for this single assay, we 
simply put the patients into rank ex-
pression order and created tertiles, 
and we used these as the low-, inter-
mediate-, and high-risk categories. 
When done this way, the results of the 
research-based Oncotype DX assay 
were in much greater agreement with 
those of the other two, as has been 
shown previously (27).
Cancer subtypes were determined 
by using the PAM50 classifier (8). 
The training set used in the reference 
PAM50 algorithm had been composed 
of 50% ER-positive samples. In the 
TCGA data set, however, there were 
approximately 80% ER-positive sam-
ples. To normalize the TCGA data sim-
ilarly to the PAM50 training set, TCGA 
messenger RNA sequencing data were 
subsampled for a group of cases that 
were 50% ER positive (freeze date, 
September 7, 2012; including 157 ER-
positive and 157 randomly selected 
ER-positive cases). The median gene 
expression value for the subset was 
determined and applied to the full 
TCGA data set prior to running the 
PAM50 algorithm (8). There were 55 
luminal A cancers, 10 luminal B can-
cers, five HER2-enriched cancers, 10 
basal-like cancers, and four normal-
like cancers in this study. Both risk of 
relapse based on subtype (ROR-S) and 
risk of relapse based on subtype and 
proliferation (ROR-P) outputs from 
PAM50 were used for analysis. The 
Figure 1
Figure 1: Schematic diagram illustrates the computer extraction of the quantitative MR imaging–based 
tumor phenotypes. DCE = dynamic contrast-enhanced.
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performance of each logistic regression 
classifier, receiver operating charac-
teristic (ROC) analysis was conducted 
For each classification task, a leave-
one-case-out cross-validation analysis 
was conducted with logistic regression 
to obtain a classifier score for each 
case (tumor). Within each cross-vali-
dation iteration, stepwise feature se-
lection with the Wilks lambda crite-
rion was conducted with subsequent 
logistic regression classifier fitting on 
these selected features. To assess the 
are all automatically extracted from the 
MR imaging data. More details are lo-
cated in Table E1 (online).
Association Analysis between MR 
imaging CEIPs and Multigene Assay 
Outputs from the Risk of Recurrence 
Models
By using the MR imaging CEIPs, we 
conducted multiple linear regression 
analysis with stepwise feature selec-
tion by using the CEIPs as independent 
variables and the continuous values 
from the “research-based” MammaP-
rint, Oncotype DX, PAM50 ROR-S, or 
PAM50 ROR-P as the response vari-
able (35), with the analysis yielding 
selected phenotypes. A P value of .05 
was used as the significance level for 
the stepwise feature selection. The 
Holm t test was applied to adjust 
for multiple testing in the regression 
models (36). For comparison, univar-
iate linear regression analyses were 
also performed between each individ-
ual MR image–based phenotype and 
the risk of recurrence scores from the 
recurrence predictor models of Mam-
maPrint, Oncotype DX, PAM50 ROR-
S, and PAM50 ROR-P.
Pilot Analysis of the Predictive Ability of 
the MR Imaging–based Phenotypes for 
Risk of Recurrence
In clinical practice, distinguishing be-
tween good and bad prognosis is of 
interest; thus, thresholding is con-
ducted on the continuous values of the 
multigene-assay tests to yield an out-
put of either good or bad prognosis. 
We assessed four binary classification 
tasks, each of which is used to predict 
good versus bad prognosis, by using 
cutoffs on the multigene test outputs 
(Table 1)—that is, (a) good prognosis 
versus bad prognosis as determined 
by using a MammaPrint cutoff, (b) 
low to medium risk of recurrence ver-
sus high risk as determined by using 
an Oncotype DX cutoff, (c) low to me-
dium risk of recurrence versus high 
risk as determined by using a PAM50 
ROR-S cutoff, and (d) low to medium 
risk of recurrence versus high risk as 
determined by using a PAM50 ROR-P 
cutoff.
Figure 2
Figure 2: Sagittal MR images in a case with a 
potentially good prognosis, a 75-year-old woman 
evaluated as having an ER-positive, PR-positive, 
HER2-negative, lymph node–negative, stage II in-
vasive breast cancer. The luminal A case is shown, 
along with the three-dimensional computer seg-
mentation (red overlay) of the primary tumor. The 
effective diameter, shape irregularity, heterogeneity 
in terms of entropy, and heterogeneity in terms 
of maximum correlation coefficient of this tumor 
are 16.8 mm, 0.438, 6.27, and 0.843, respec-
tively, with ranges of 7.8–54.0 mm, 0.40–0.84, 
6.00–6.59, and 0.646–0.925.
Figure 3
Figure 3: Sagittal MR images in a case with a 
potentially poor prognosis, a 44-year-old woman 
evaluated as having an ER-negative, PR-negative, 
HER2-negative, lymph node–negative, stage II in-
vasive breast cancer. The basal-like case is shown, 
along with the three-dimensional computer seg-
mentation (red overlay) of the primary tumor. The 
effective diameter, shape irregularity, heterogeneity 
in terms of entropy, and heterogeneity in terms 
of maximum correlation coefficient of this tumor 
are 21.7 mm, 0.592, 6.51, and 0.732, respec-
tively, with ranges of 7.8–54.0 mm, 0.40–0.84, 
6.00–6.59, and 0.646–0.925.
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Positive correlation between the 
selected MR imaging phenotypes of 
size (effective diameter) and nega-
tive correlation with enhancement 
texture (maximum correlation coeffi-
cient) and increasing levels of risk of 
phenotype and the four risks of re-
currence scores are shown in Figure 4
. Some phenotypes correlate similarly 
(ie, similar color on the color scale) 
across the risk estimate models, while 
others do not.
(by using the semiparametric “proper” 
binormal ROC model [37–39]) with 
the classifier scores as the decision 
variable, with the area under the ROC 
curve serving as the figure of merit. All 
analysis routines were written in Mat-
Lab (version 8.0, MathWorks, Natick, 
Mass).
Results
Figures 2 and 3 show examples of MR 
images in two cases: a case of a po-
tentially good prognosis and a case of 
a potentially bad prognosis, along with 
the computer segmentations of the pri-
mary tumors. An enlarged view of each 
tumor is also shown to demonstrate the 
heterogeneity of uptake values within 
the tumor. The corresponding CEIP 
characteristics are also given.
The multiple linear regression 
analyses demonstrated significant as-
sociations (R2 = 0.25–0.32, r = 0.50–
0.56, P , .0001) between selected 
CEIP signatures and the multigene 
assay recurrence scores (Tables 2, 3
). Key CEIPs from stepwise feature 
selection included tumor size and en-
hancement texture, characterizing 
lesion heterogeneity. Overall, results 
from all four multiple linear regression 
analyses indicate that tumors with 
a high risk of recurrence tend to be 
larger and show more heterogeneous 
enhancement patterns.
A correlation heat map based on 
univariate linear regression analysis 
between each individual MR imaging 
Table 2
Associations from Multiple Linear 
Regression Analysis between CEIPs 
and Risk of Recurrence Scores
Research Gene  
Assay Goodness of Fit P Value
MammaPrint R 2 = 0.30, r = 0.55 ,.0001
Oncotype DX R 2 = 0.25, r = 0.5 ,.0001
PAM50 ROR-S R 2 = 0.32, r = 0.56 ,.0001
PAM50 ROR-P R 2 = 0.28, r = 0.53 ,.0001
Note.—R2 is the coefficient of determination, which 
indicates how well the data fit a linear model, and r is 
the correlation coefficient.
Figure 4
Figure 4: Color map shows the correlation of the MR imaging–based phenotypes with the recurrence pre-
dictor models of MammoPrint, Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P. For this color scale, yellow 
indicates higher correlation as compared with blue. The different gene assays (recurrence predictor models) 
serve as our “reference standard” in this study.
Table 3
Associations between CEIPs and Risk of Recurrence Scores according to the Multiple 
Linear Regression Model
Research Gene Assay and 
Phenotypic Category Feature Regression Coefficient P Value
MammaPrint Constant 29.60 .0070
 Enhancement texture Maximum correlation coefficient 3.14 .00021
 Enhancement texture Sum average 0.22 .011
 Size Effective diameter 20.020 .0019
Oncotype DX Constant 161.52 .00073
 Kinetic curve assessment Maximum enhancement 10.30 .014
 Enhancement texture Maximum correlation coefficient 2200.23 .0015
 Size Effective diameter 1.89 .00030
PAM50 ROR-S Constant 491.36 .012
 Enhancement texture Maximum correlation coefficient 2182.33 .00011
 Enhancement texture Sum average 29.87 .039
 Size Effective diameter 1.23 .00044
PAM50 ROR-P Constant 97.51 .0013
 Kinetic curve assessment Uptake rate 384.68 .033
 Enhancement texture Maximum correlation coefficient 2138.98 .00057
 Size Effective diameter 1.35 ,.0001
Note.—The Holm t test was applied for correcting of multiple testing.
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Discussion
The association analysis between the 
CEIPs and the risk of recurrence scores 
from various gene-assay models yielded 
moderate correlations. The MR imag-
ing phenotypes selected from multiple 
linear regression analyses were related 
to breast tumor size, enhancement tex-
ture, and characteristics of the kinetic 
curve. Similar, negatively correlated 
relationships between the MR imag-
ing phenotype of enhancement texture 
(maximum correlation coefficient) and 
the recurrence scores were observed 
across all four recurrence models. 
Since enhancement texture is calculated 
on the MR image acquired at the first 
postcontrast time point, these enhance-
ment texture phenotypes quantitatively 
characterize the heterogeneous nature 
of contrast material uptake within the 
breast tumor. The smaller the enhance-
ment texture, the more heterogeneous 
the tumor, which appears to indicate a 
higher risk of recurrence. Assessment 
of heterogeneity by using a noninva-
sive method such as imaging may be 
important in the future as more target-
able agents are used for treating breast 
cancer and in the neoadjuvant setting 
in monitoring treatment response. As 
we understand that breast cancers can 
be extremely heterogeneous, harbor-
ing multiple driver mutations that may 
change over time, having a method 
to assess heterogeneity is likely use-
ful. Assessment of heterogeneity may 
set prognostic expectations and affect 
treatment options.
Understanding the relationships be-
tween gene expression profiles, imaging 
phenotypes, and outcomes like recur-
rence risk has the potential to provide 
insights into the complex cancer biology 
at work in each individual patient. Cur-
rently, gene expression profiles are in-
creasingly helping to distinguish tumor 
types beyond features that are evident 
at conventional histopathologic exami-
nation. In the future, CEIPs have the po-
tential to compliment these expression 
profiles by demonstrating anatomic and 
functional characteristics that might 
improve prediction of recurrence or 
other important outcomes. Our finding 
(standard error, 0.06), 0.68 (standard 
error, 0.08), and 0.55 (standard error, 
0.09) for MammaPrint, Oncotype DX, 
PAM50 ROR-S, and PAM50 ROR-P, re-
spectively, with all but the latter show-
ing statistical difference from chance 
(Fig 6). Of note, we realize that the 
Oncotype DX gene assay is usually 
conducted clinically only in ER-positive 
cases, but the result shown here is for 
all cases used in this study.
recurrence for MammaPrint, Onco-
type DX, PAM50 ROR-S, and PAM50 
ROR-P were observed (Fig 5). Note 
that a low value of this enhancement 
texture feature infers a more hetero-
geneous enhancement pattern.
Use of the CEIPs in the tasks of 
distinguishing between low to medium 
and high risk levels of recurrence yield-
ed area under the ROC curve values 
of 0.88 (standard error, 0.05), 0.76 
Figure 5
Figure 5: Box and whisker plots show the relationship of the MR imaging–based phenotypes of, A, size 
(effective diameter) and, B, enhancement texture (maximum correlation coefficient) with the recurrence 
predictor models of MammaPrint, Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P. Note that a low value of 
this texture feature infers a more heterogeneous enhancement pattern.
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use the risk status for a given cancer 
as the surrogate marker. Also, cases 
used in this study were predetermined 
according to TCGA inclusion criteria. 
Most women in this study had core 
biopsy–proven invasive breast cancer 
before undergoing MR imaging exam-
inations, which may confound our find-
ings in this study in terms of hetero-
geneity in enhancement pattern. Thus, 
the results in this study need further 
validation in a larger data set to bet-
ter assess its potential clinical use in 
the future. Even with these limitations, 
the TCGA data set is currently still the 
largest publicly available data set for 
this radiomics research.
In conclusion, the results in this 
study indicate that quantitative MR 
imaging radiomics shows promise as 
a means for image-based phenotyping 
in assessing the risk of cancer recur-
rence. Merging imaging phenotypes 
with genomic data in the future may 
lead to improved survival predictors. 
Such quantitative radiomic prognostic 
models of breast cancer may potentially 
be useful for precision medicine and af-
fect patient treatment strategy.
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expect similar results (3–9). Also, we 
only analyzed dynamic contrast-en-
hanced MR images and not T2-weight-
ed or diffusion-weighted images. One 
would expect improved performance 
by using multiparametric breast MR 
images; thus, we will analyze those 
in the future. In addition, the MR im-
ages used in this study were acquired 
from multiple institutions with vari-
ous acquisition protocols. Given the 
improved MR imaging technology and 
standardized imaging acquisition pro-
tocols, we would expect in the future 
to see even more association with risk 
of recurrence. Case composition, such 
as the distribution of ER-positive cases 
(87%) and ER-negative cases (13%), is 
different from the general clinical pop-
ulation distribution, which is usually 
approximately a 2:1 ratio. In addition, 
there were many “good prognosis” 
cancer cases in the study. The ground 
truth used in this study was the esti-
mated risk of recurrence instead of ac-
tual survival information, as it was not 
available for the study. Thus, we had to 
that enhancement texture features are 
consistently associated with recurrence 
score may indicate that internal tumor 
architecture, such as microvascular 
density (ie, tumor-related angiogene-
sis) and/or central necrosis are playing 
a biological role that is important in re-
currence. While strongly asserting this 
connection between gene expression 
and imaging demonstrates that a key to 
prognosis may be premature on the ba-
sis of our current results, understanding 
these patterns holds promise for untan-
gling how gene expression in concert 
with in vivo imaging features map to 
both biological molecular mechanisms 
and outcomes.
There are some limitations of this 
study, such as the small data set, since 
breast MR images are not available 
for most of the TCGA breast cancer 
cases. Another limitation was that the 
scores for risk of recurrence (Mam-
maPrint, Oncotype DX, and PAM50) 
were obtained from research-based 
determinations and not from the ac-
tual clinical tests, although one would 
Figure 6
Figure 6: ROC curves for the leave-one-case-out logistic regression 
classifiers by using CEIPs as the decision variable in the tasks of distinguishing 
between low to medium and high risk levels of recurrence for MammaPrint, 
Oncotype DX, PAM50 ROR-S, and PAM50 ROR-P, respectively.
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